PURPOSE: Choroidal neovascularization (CNV) secondary to traumatic rupture of Bruch's membrane is a rare condition, without standardized treatment. Here we describe one case of CNV related to traumatic rupture of Bruch's membrane which was successfully treated with intravitreal injection of ranibizumab. METHODS: A 14-year-old patient was referred for ocular contusion, complicating interpapillomacular rupture of Bruch's membrane in left eye. Indeed, a correct initial visual acuity, juxtafoveolar CNV appeared 4 months later on the border of Bruch's membrane rupture. The patient was treated with an off-label intravitreal ranibizumab because of worsening of visual acuity. RESULTS: One month after intravitreal injection, visual acuity improved, from 20/40 to 20/25. At 12-month follow-up, visual acuity remained at 20/25, fundus examination. Fluorescein angiography, indocyanine green angiography and optic coherence tomography showed fibrotic evolution of CNV. The Bruch's membrane rupture remained stable. No side-effect of intravitreal injection of ranibizumab was observed. CONCLUSION: For this patient affected with CNV secondary to traumatic Bruch's membrane, one single intravitreal ranibizumab injection was efficient, with 1-year follow-up.
PURPOSE: Choroidal neovascularization (CNV) secondary to traumatic rupture of Bruch's membrane is a rare condition, without standardized treatment. Here we describe one case of CNV related to traumatic rupture of Bruch's membrane which was successfully treated with intravitreal injection of ranibizumab. METHODS: A 14-year-old patient was referred for ocular contusion, complicating interpapillomacular rupture of Bruch's membrane in left eye. Indeed, a correct initial visual acuity, juxtafoveolar CNV appeared 4 months later on the border of Bruch's membrane rupture. The patient was treated with an off-label intravitreal ranibizumab because of worsening of visual acuity. RESULTS: One month after intravitreal injection, visual acuity improved, from 20/40 to 20/25. At 12-month follow-up, visual acuity remained at 20/25, fundus examination. Fluorescein angiography, indocyanine green angiography and optic coherence tomography showed fibrotic evolution of CNV. The Bruch's membrane rupture remained stable. No side-effect of intravitreal injection of ranibizumab was observed. CONCLUSION: For this patient affected with CNV secondary to traumatic Bruch's membrane, one single intravitreal ranibizumab injection was efficient, with 1-year follow-up.
Authors: Hyeong Gon Yu; Xiaoqing Liu; Szilard Kiss; Edward Connolly; Evangelos S Gragoudas; Norman A Michaud; Oleg V Bulgakov; Michael Adamian; Margaret M DeAngelis; Joan W Miller; Tiansen Li; Ivana K Kim Journal: Invest Ophthalmol Vis Sci Date: 2008-02-22 Impact factor: 4.799
Authors: Rufino M Silva; José M Ruiz-Moreno; João Nascimento; Angela Carneiro; Paulo Rosa; Augusto Barbosaa; Fausto Carvalheira; J Rui Faria Abreu; José G Cunha-Vaz Journal: Retina Date: 2008-10 Impact factor: 4.256
Authors: Joseph D Benevento; Rama D Jager; A Gwendolyn Noble; Paul Latkany; William F Mieler; Mari Sautter; Sanford Meyers; Marilyn Mets; Michael A Grassi; Peter Rabiah; Kenneth Boyer; Charles Swisher; Rima McLeod Journal: Arch Ophthalmol Date: 2008-08
Authors: Dante J Pieramici; Melvin Rabena; Alessandro A Castellarin; Ma'an Nasir; Robert See; Tamara Norton; Andres Sanchez; Sarah Risard; Robert L Avery Journal: Ophthalmology Date: 2008-08-16 Impact factor: 12.079
Authors: Sophie J Bakri; Melissa R Snyder; Joel M Reid; Jose S Pulido; Mohamed K Ezzat; Ravinder J Singh Journal: Ophthalmology Date: 2007-12 Impact factor: 12.079